Losapotatab1 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 01)
Losartan Potassium Tablet, Film Coated
Product Images NDC 82009-044
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 82009-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Losapotatab2 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 02)
This appears to be a portion of a clinical study graph showing the percentage of patients reaching the primary endpoint over time for two medications, Atenolol and Losartan Potassium. There is also information regarding an adjusted risk reduction of 13% with a p-value of 0.021. The study is measured in months, with time points at 18, 24, 30, 36, 42, 48, 54, 60, and 66 months.*
Losapotatab3 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 03)
The text provided appears to be a data table showing the results of a study comparing the effects of two medications on the risk of fatal vs. non-fatal stroke in patients. The medications studied are Atenolol and Losartan Potassium. The table displays the percentage of patients in the study who experienced a stroke over a period of 66 months, with measurements taken at regular intervals. The table also includes information on the adjusted risk reduction associated with each medication, which was 25% for Losartan Potassium (p=0.001). The significance or methodology of the study, however, is not available due to incomplete data.*
Losapotatab (D1af6550 E4ba 4015 8b4a 11caab0b95f6 04)
Losapotatab5 (D1af6550 E4ba 4015 8b4a 11caab0b95f6 05)
This appears to be a table showing the percentage of patients with an event in a clinical trial for Losartan Potassium Tablet compared to a placebo group, with a risk reduction of 16.1% and a p-value of 0.022. However, the rest of the text and numbers are not clear or don't make sense, so further context is needed to fully understand the data.*
Losapotataba (D1af6550 E4ba 4015 8b4a 11caab0b95f6 06)
Losartan Potassium Tablets, USP is a medication packaged in a container with 1,000 tablets. Each tablet contains 26 mg of Losartan Potassium, USP. The package insert provides information on usual dosage and complete prescribing information. The tablets must be stored at 20°C to 25°C (66 to 77°F) and kept protected from light in a tightly closed container. The pharmaceutical product must be kept out of the reach of children. The manufacturer, Zydus Lifesciences Ltd, is based in Ahmedabad, India, and the product is manufactured for Qualem Pharmaceuticals Health Ltd, located at 20 Genesis Close in Cayman, kv1-1208.*
Losapotatabb (D1af6550 E4ba 4015 8b4a 11caab0b95f6 07)
This is a description of a medication named "Losartan Potassium Tablets, USP" with each tablet containing 50mg of losartan potassium. The package contains 1,000 tablets and the recommended storage temperature is between 20°C to 25°C (66 to 77°F). The medication should be stored in a tightly closed and light-resistant container and kept away from the reach of children. The medication is manufactured by Zydus Life Sciences Ltd., located in Ahmedabad, India, and is produced for Qualem Pharmaceuticals Health LLC, with a mailing address listed in the Cayman Islands.*
Losapotatabc (D1af6550 E4ba 4015 8b4a 11caab0b95f6 08)
This is a description of a bottle of Losartan Potassium Tablets, USP containing 1,000 tablets, each with 100mg of losartan potassium, manufactured by Zydus Lifescences Ltd in Ahmedabad, India. The usual dosage and complete prescribing information can be found in the package insert, and the tablets should be stored between 20°C to 25°C (68°F to 77°F) in a tight, light-resistant container. Keep the container closed and protected from light, and keep this and all drugs out of the reach of children. The bottle was manufactured for Quallent Pharmaceuticals Health LLG located in Grand Cayman, KY1-1208, Cayman Islands.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
